PAVmed reports Q2 non-GAAP EPS (5c) vs. (84c) last year

Reports Q2 revenue $6K vs. $979K last year. PAVmed (PAVM) had cash and cash equivalents of $4.0M as of June 30, 2025,vs. $1.2M as of December 31, 2024. “PAVmed has stabilized its corporate structure, strengthened its balance sheet, and is positioned to advance its vision as a diversified commercial life sciences company with multiple independently-financed subsidiaries operating under a shared services model,” said CEO Lishan Aklog. “The successful second quarter financings of both Lucid and Veris reflect investor confidence in their commercial potential and provide each company with capital needed to achieve important near-term milestones. Veris is now aggressively advancing towards final development and regulatory clearance of its implantable monitor, as well as completion the final steps toward full commercial engagement with our strategic partner, OSU-The James. We remain actively engaged in evaluating new opportunities to leverage PAVmed’s platform and further diversify our portfolio.”